# CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

> **NCT00096239** · PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** CP-547,632

## Key facts

- **NCT ID:** NCT00096239
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** 2005-02
- **Target enrollment:** — (—)
- **Last updated:** 2013-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00096239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00096239, "CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00096239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*